P47.09 Tepotinib + Osimertinib for EGFR-Mutant NSCLC with Resistance to First-Line Osimertinib Due to MET amplification: INSIGHT 2
2021
-
Correction
-
Source
-
Cite
-
Save
0
References
0
Citations
NaN
KQI